Holen Sie sich die Stockscreener-App
10.02
4.75%
-0.50
Handel nachbörslich:
10.03
0.010
+0.10%
Schlusskurs vom Vortag:
$10.52
Offen:
$10.62
24-Stunden-Volumen:
99,157
Relative Volume:
0.46
Marktkapitalisierung:
$382.96M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
3.3851
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
-0.30%
1M Leistung:
-5.38%
6M Leistung:
+32.36%
1J Leistung:
-38.22%
1-Tages-Spanne:
$9.99
$10.70
1-Wochen-Bereich:
$9.87
$10.88
52-Wochen-Spanne:
$4.93
$16.07
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.02 | 402.07M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada updates progress in preclinical pipeline - BioWorld MedTech
Entrada Therapeutics reports progress across development portfolio - Yahoo Finance
Is Entrada Therapeutics Inc. stock safe for conservative investorsQuarterly Investment Review & AI Driven Stock Reports - ulpravda.ru
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risks2025 Market Trends & Accurate Technical Buy Alerts - ulpravda.ru
What insider trading reveals about Entrada Therapeutics Inc. stockJuly 2025 Review & Growth Focused Stock Reports - ulpravda.ru
Entrada Therapeutics Highlights Progress Across Its Portfolio of Rna-Based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - MarketScreener
Entrada Therapeutics highlights RNA pipeline progress and outlook - TipRanks
Entrada reports progress on DMD treatments, shares clinical timeline By Investing.com - Investing.com Australia
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection - Quiver Quantitative
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Azenta elects Entrada CEO to Board of Directors - MSN
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - moha.gov.vn
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
Entrada Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Kory James Wentworth Sells 8,910 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Insider Sell: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus
Entrada Therapeutics CFO Sells Shares Under Trading Plan - TradingView
CFO Wentworth Sells 8,910 ($88.9K) Of Entrada Therapeutics Inc [TRDA] - TradingView
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CFO Wentworth Files To Sell 8,910 Of Entrada Therapeutics Inc [TRDA] - TradingView
Will Entrada Therapeutics Inc. stock deliver shareholder valueWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Entrada Therapeutics (TRDA) Price Target Decreased by 10.81% to 16.83 - MSN
Why Entrada Therapeutics Inc. stock is favored by pension fundsTrade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
(TRDA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
How risky is Entrada Therapeutics Inc. stock now2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):